Preemptive administration of recombinant factor VII (rVIIa) in patients transplanted due to fulminant Wilson's disease.
BACKGROUND
Fulminant liver failure (FLF) is a severe clinical condition usually accompanied by a coagulopathy, which is one of the key selection criteria for liver transplantation. Prolongation of prothrombin time can vary between etiologies of FHF, being one of the worst in fulminant presentation of Wilson's disease. Although INR value is not predictive for hemorrhage, it is commonly accepted that INR >1.9 carries a substantial risk of intraoperative bleeding. We tested the hypothesis that preemptive administration of recombinant factor VII (rFVIIa) is a safe and efficacious approach allowing performance of urgent liver transplantation without significant bleeding and thrombotic complications.


METHODS
In 14 analyzed cases of fulminant Wilson's disease subjected for orthotopic liver transplantation (OLT), a single bolus of rFVIIa 10 minutes before skin incision was given routinely in a median dose of 55.9 microg/kg.


RESULTS
Median value of INR dropped from 3.1 to 1.2 30 minutes after rFVIIa administration. Transfusion requirements in those cases did not differ from standard transfusion requirements of PRBCs observed in elective OLTx in our center (6 units v. 5, respectively). Recurrent bleeding was noted in 1 patient with the rupture of aorta. One-year survival rate in the studied group was 85.7%. Thrombotic complications were noted in none of the patients.


CONCLUSIONS
We conclude that preemptive use of rFVIIa allows performance of a broad surgical procedure without hemorrhagic complications and without increased risk of thromboembolic events in patients with severe coagulopathy.
Czuprynska
Maria M
MM
Marie Curie Hospital, Szczecin, Poland.
Wawrzynowicz-Syczewska
Marta
M
Jureczko
Lidia
L
Andrzejewska
Janina
J
Jarosz
Konrad
K
Trzebicki
Janusz
J
Pacholczyk
Marek
M
Chmura
Andrzej
A
Wojcicki
Maciej
M
D000293:Adolescent; D000328:Adult; D001778:Blood Coagulation Disorders / Q000188:drug therapy / Q000209:etiology; D016063:Blood Loss, Surgical / Q000517:prevention & control; D015942:Factor VIIa / Q000008:administration & dosage*; D005260:Female; D006527:Hepatolenticular Degeneration / Q000150:complications / Q000209:etiology / Q000601:surgery*; D006801:Humans; D017114:Liver Failure, Acute / Q000150:complications / Q000209:etiology / Q000601:surgery; D016031:Liver Transplantation / Q000009:adverse effects; D008297:Male; D011517:Prothrombin Time; D011994:Recombinant Proteins / Q000008:administration & dosage; D012189:Retrospective Studies; D015996:Survival Rate; D065227:Transfusion Reaction; D055815:Young Adult
D011994:Recombinant Proteins; D015942:Factor VIIa